Lipodystrophy is associated with a low rate of treatment failure in HIV-positive patients switched to atazanavir.
Zaccarelli
Mauro
M
Zinzi
Daniela
D
Trotta
Maria Paola
MP
Liuzzi
Giuseppina
G
Sette
Pietro
P
Marconi
Patrizia
P
Acinapura
Rosa
R
Antinori
Andrea
A
D000069446:Atazanavir Sulfate; D006679:HIV Seropositivity / Q000188:drug therapy*; D039682:HIV-Associated Lipodystrophy Syndrome / Q000453:epidemiology*; D006801:Humans; D009842:Oligopeptides / Q000009:adverse effects / Q000627:therapeutic use*; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D013557:Switzerland / Q000453:epidemiology; D017211:Treatment Failure; D016312:Treatment Refusal
D009842:Oligopeptides; D011725:Pyridines; D000069446:Atazanavir Sulfate